Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Trial ID or NCT#
NCT02717455
Status
NOT RECRUITING
Purpose
This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG or H3K27+Thalamic Diffuse Malignant Glioma (DMG) that has not yet gotten worse.
Official Title
Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma
Eligibility Criteria
Ages Eligible for Study: 2 Years to 21 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Investigator(s)
Michelle Monje
Paul Graham Fisher, MD
Neuro-oncologist,
Pediatric neurologist
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Contact us to find out if this trial is right for you.
Contact
Stefania Ursu Chirita
650-723-1423
View on ClinicalTrials.gov
